Present status and future prospects for the hybridoma technology
- PMID: 6976303
- DOI: 10.1007/BF02618605
Present status and future prospects for the hybridoma technology
Abstract
A somatic cell genetic technique has recently been developed that makes it possible to obtain very large amounts of homogeneous antibodies and to replenish the supply of the exact same antibodies whenever they are needed. This hybridoma technology has already contributed to major scientific advances and will surely improve the diagnosis and treatment of many diseases. Because the technology itself is relatively simple and inexpensive, it has captured the attention of basic scientists, clinicians, and industrial managers and investors.
Similar articles
-
Monoclonal antibodies in clinical immunology.Clin Chem. 1981 Nov;27(11):1797-806. Clin Chem. 1981. PMID: 7028317 Review.
-
Mapping of SJL/J reticulum cell sarcoma tumor-associated Ia antigens by T cell hybridomas: characterization of tumor-specific and shared epitopes detected on IE+ allogeneic cells.J Immunol. 1986 Jul 15;137(2):733-40. J Immunol. 1986. PMID: 2424977
-
Monoclonal antibodies in urology.J Urol. 1983 Sep;130(3):584-92. doi: 10.1016/s0022-5347(17)51319-1. J Urol. 1983. PMID: 6350618 Review.
-
Generation of Murine Monoclonal Antibodies by Hybridoma Technology.J Vis Exp. 2017 Jan 2;(119):54832. doi: 10.3791/54832. J Vis Exp. 2017. PMID: 28117810 Free PMC article.
-
Monoclonal hybridoma antibodies in human melanoma: current status.Int Adv Surg Oncol. 1984;7:241-70. Int Adv Surg Oncol. 1984. PMID: 6205999